Noria Therapeutics

Noria Therapeutics is a radiopharmaceutical company specializing in the development of targeted alpha therapies (TATs) and theranostic agents for oncology. Founded in 2017 by Dr. John Babich, the company utilizes technology licensed from Weill Cornell Medicine and Johns Hopkins University to create precision radiotherapeutics. Its lead program is an actinium-225 labeled small molecule targeting prostate-specific membrane antigen (PSMA) for the treatment of prostate cancer. In June 2021, Noria and its subsidiary PSMA Therapeutics were acquired by Bayer to expand its radiopharmaceutical portfolio and bolster its oncology pipeline. The company also developed NTI-1309, a fibroblast activation protein (FAP) targeting imaging agent, which was licensed to Lantheus.